What the trial was testing
The CAMEO-DAPA enrolled 38 patients with heart failure. The study was sponsored by Mayo Clinic and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Dapagliflozin improved lung blood vessel flexibility and right heart function during exercise in heart failure patients.
JAMA cardiology · 2024 · NCT04730947
These findings — that the pill made lung blood vessels more flexible during exercise compared to placebo — were published in the JAMA cardiology and represent the headline result of the study.
Researchers tracked outcomes across 38 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with heart failure, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This treatment is FDA-approved for heart failure with preserved ejection fraction. If you have this type of heart failure, ask your doctor whether dapagliflozin might help you — especially if you struggle with exercise or shortness of breath. This study found it helped the right side of the heart work more efficiently during activity.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open heart failure trials
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
This is a pharmacokinetic study (PK Study) to better understand empagliflozin dosing in pediatric Duchenne muscular dystrophy patients. Empagliflozin is currently used off-label in this population due to the mortality benefits seen in adult cardiomyopathy and heart failure. Investigators will perform PK studies in DMD patients of various ages and weights to better understand the PK profile (absorption, distribution, metabolism, excretion) and dosing to better treat Duchenne cardiomyopathy.